Ayr Strategies
Market Cap
CA$1.4b
Last Updated
2021/01/21 23:42 UTC
Data Sources
Company Financials +
Executive Summary
Ayr Strategies Inc., a vertically-integrated cannabis multi-state operator, cultivates, manufactures, and retails branded cannabis products cannabis products and branded cannabis packaged goods. More Details
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Ayr Strategies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AYR.A is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: AYR.A's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
4.6%
AYR.A
3.0%
CA Pharmaceuticals
0.7%
CA Market
1 Year Return
168.4%
AYR.A
49.4%
CA Pharmaceuticals
2.1%
CA Market
Return vs Industry: AYR.A exceeded the Canadian Pharmaceuticals industry which returned 49.4% over the past year.
Return vs Market: AYR.A exceeded the Canadian Market which returned 2.1% over the past year.
Shareholder returns
| AYR.A | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.6% | 3.0% | 0.7% |
| 30 Day | 31.6% | 32.8% | 4.6% |
| 90 Day | 85.7% | 71.2% | 13.5% |
| 1 Year | 168.4%168.4% | 49.4%49.4% | 5.8%2.1% |
| 3 Year | n/a | -51.7%-52.4% | 13.9%3.1% |
| 5 Year | n/a | 413.7%410.0% | 67.3%41.6% |
Long-Term Price Volatility Vs. Market
How volatile is Ayr Strategies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Ayr Strategies Inc.'s (CSE:AYR.A) Has Found A Path To Profitability2 months ago | Simply Wall St
Does Ayr Strategies's (CSE:AYR.A) Statutory Profit Adequately Reflect Its Underlying Profit?3 months ago | Simply Wall St
Should Ayr Strategies (CSE:AYR.A) Be Disappointed With Their 73% Profit?Valuation
Is Ayr Strategies undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AYR.A (CA$36.66) is trading below our estimate of fair value (CA$468.97)
Significantly Below Fair Value: AYR.A is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AYR.A is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: AYR.A is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AYR.A's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AYR.A is overvalued based on its PB Ratio (4.9x) compared to the CA Pharmaceuticals industry average (2.6x).
Next Steps
Future Growth
How is Ayr Strategies forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
62.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AYR.A is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: AYR.A is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AYR.A's is expected to become profitable in the next 3 years.
Revenue vs Market: AYR.A's revenue (43.7% per year) is forecast to grow faster than the Canadian market (8% per year).
High Growth Revenue: AYR.A's revenue (43.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AYR.A's Return on Equity is forecast to be high in 3 years time (20.5%)
Next Steps
Past Performance
How has Ayr Strategies performed over the past 5 years?
73.7%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: AYR.A is currently unprofitable.
Growing Profit Margin: AYR.A is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AYR.A's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AYR.A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AYR.A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-61.1%).
Return on Equity
High ROE: AYR.A has a negative Return on Equity (-30.37%), as it is currently unprofitable.
Next Steps
Financial Health
How is Ayr Strategies's financial position?
Financial Position Analysis
Short Term Liabilities: AYR.A's short term assets ($75.7M) exceed its short term liabilities ($49.5M).
Long Term Liabilities: AYR.A's short term assets ($75.7M) do not cover its long term liabilities ($181.0M).
Debt to Equity History and Analysis
Debt Level: AYR.A's debt to equity ratio (24.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if AYR.A's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AYR.A has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AYR.A is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 90.2% per year.
Next Steps
Dividend
What is Ayr Strategies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AYR.A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AYR.A's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AYR.A's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AYR.A's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AYR.A's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.8yrs
Average management tenure
CEO
Jon Sandelman (62 yo)
no data
Tenure
US$257,328
Compensation
Mr. Jonathan Everett Sandelman, also known as Jon, J.D., is the Chairman, Chief Executive Officer and Corporate Secretary of Ayr Strategies Inc and has been its Director since September 25, 2017. He has be...
CEO Compensation Analysis
Compensation vs Market: Jon's total compensation ($USD257.33K) is below average for companies of similar size in the Canadian market ($USD1.19M).
Compensation vs Earnings: Insufficient data to compare Jon's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | no data | US$257.33k | 9.48% $ 129.1m | |
| Chief Financial Officer | 1.17yrs | US$131.11k | no data | |
| Chief Operating Officer | no data | US$227.06k | 0.026% $ 351.1k | |
| Chief Integration Officer | 1.17yrs | US$48.29k | no data | |
| Head of Strategy and M&A | no data | US$211.92k | 0.074% $ 1.0m | |
| Head of Investor Relations | 0.42yr | no data | no data | |
| Head of Human Resources | 0.42yr | no data | no data | |
| Chief Development Officer | no data | no data | no data |
0.8yrs
Average Tenure
Experienced Management: AYR.A's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | no data | US$257.33k | 9.48% $ 129.1m | |
| Independent Director | 2.08yrs | US$30.27k | 0.022% $ 298.4k | |
| Director | 1.67yrs | no data | 0.043% $ 587.8k | |
| Independent Director | 3.33yrs | US$35.12k | 0.15% $ 2.1m | |
| Director | 1.67yrs | no data | 0.0013% $ 17.6k | |
| Independent Director | 0.42yr | no data | 0.31% $ 4.3m |
1.7yrs
Average Tenure
58.5yo
Average Age
Experienced Board: AYR.A's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AYR.A insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.4%.
Top Shareholders
Company Information
Ayr Strategies Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Ayr Strategies Inc.
- Ticker: AYR.A
- Exchange: CNSX
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$1.363b
- Shares outstanding: 38.81m
- Website: https://www.ayrstrategies.com
Location
- Ayr Strategies Inc.
- 590 Madison Avenue
- 26th Floor
- New York
- New York
- 10022
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AYR.A | CNSX (Canadian National Stock Exchange) | Yes | Non-Multiple Voting Shares | CA | CAD | May 2019 |
| AYRW.F | OTCPK (Pink Sheets LLC) | Yes | Non-Multiple Voting Shares | US | USD | May 2019 |
| 3KJA | DB (Deutsche Boerse AG) | Yes | Non-Multiple Voting Shares | DE | EUR | May 2019 |
Biography
Ayr Strategies Inc., a vertically-integrated cannabis multi-state operator, cultivates, manufactures, and retails branded cannabis products cannabis products and branded cannabis packaged goods. The compan...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 23:42 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.